.d-about-spiriva,
.d-about-spiriva * {
    box-sizing: border-box;
}

.d-about-spiriva {
    background: #f6f5f3;
    height: 168.375rem;
    position: relative;
    overflow: hidden;
}

.group-861 {
    position: absolute;
    inset: 0;
}

.rectangle-28 {
    background: #ffffff;
    width: 78rem;
    height: 2.8125rem;
    position: absolute;
    left: 0rem;
    top: 0rem;
}

.for-healthcare-professionals {
    color: #191919;
    text-align: left;
    font-family: "BoehringerForwardText-MdItalic", sans-serif;
    font-size: 0.875rem;
    font-weight: 400;
    font-style: italic;
    position: absolute;
    left: 4.6875rem;
    top: 0.3rem;
}

.group-859 {
    width: 100%; /*78rem;*/
    height: 6rem;
    position: static;
}

.rectangle-27 {
    background: #08312a;
    width: 100%; /*78rem*/
    height: 5rem;
    position: absolute;
    left: 0rem;
    top: 2rem;
}

.frame-943 {
    background: #00e47c;
    padding: 0.875rem 1.5rem 0.875rem 1.5rem;
    display: flex;
    flex-direction: row;
    gap: 0.625rem;
    align-items: center;
    justify-content: center;
    height: 3rem;
    position: absolute;
    left: 68.625rem;
    top: 4.3125rem;
}

.rate-this-site {
    color: #08312a;
    text-align: left;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 1rem;
    font-weight: 400;
    position: relative;
}

.image-9 {
    width: 10rem;
    height: 3.03rem;
    position: absolute;
    left: 4.6875rem;
    top: 3.2975rem;
    object-fit: cover;
}

.frame-950 {
    display: flex;
    flex-direction: row;
    gap: 2rem;
    align-items: center;
    justify-content: flex-start;
    position: absolute;
    left: 18.1875rem;
    top: 4.15625rem;
}

.products {
    color: #ffffff;
    text-align: left;
    font-family: "BoehringerForwardText-Md", sans-serif;
    font-size: 1rem;
    font-weight: 400;
    position: relative;
}

.therapeutic-areas {
    color: #ffffff;
    text-align: left;
    font-family: "BoehringerForwardText-Md", sans-serif;
    font-size: 1rem;
    font-weight: 400;
    position: relative;
}

.resources-and-services {
    color: #ffffff;
    text-align: left;
    font-family: "BoehringerForwardText-Md", sans-serif;
    font-size: 1rem;
    font-weight: 400;
    position: relative;
}

.vector {
    width: 1.25rem;
    height: 1.25rem;
    position: absolute;
    left: 75 rem;
    top: 5.1875rem;
    overflow: visible;
}

.line-28 {
    margin-top: -0.0625rem;
    border-style: solid;
    border-color: #00e47c;
    border-width: 0.0625rem 0 0 0;
    width: 4.3125rem;
    height: 0rem;
    position: absolute;
    left: 18.1875rem;
    top: 6.53125rem;
}

.group-860 {
    width: 100%; /*78rem;*/
    height: 3.5625rem;
    position: static;
}

.group-858 {
    width: 100%; /*78rem;*/
    height: 3.5625rem;
    position: static;
}

.rectangle-35 {
    background: #ffffff;
    width: 78rem;
    height: 3.5625rem;
    position: absolute;
    left: 0rem;
    top: 16.3125rem;
}

.frame-946 {
    display: flex;
    flex-direction: row;
    gap: 2rem;
    align-items: center;
    justify-content: flex-start;
    position: absolute;
    left: 4.6875rem;
    top: 17.4375rem;
}

.frame-944 {
    display: flex;
    flex-direction: row;
    gap: 0.5rem;
    align-items: center;
    justify-content: flex-start;
    flex-shrink: 0;
    position: relative;
}

.about-spiriva {
    color: #08312a;
    text-align: left;
    font-family: "BoehringerForwardText-Md", sans-serif;
    font-size: 1rem;
    font-weight: 400;
    position: relative;
}

.frame-945 {
    display: flex;
    flex-direction: row;
    gap: 0.5rem;
    align-items: center;
    justify-content: flex-start;
    flex-shrink: 0;
    position: relative;
}

.lama-treatment {
    color: #2e2d2c;
    text-align: left;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 1rem;
    font-weight: 400;
    position: relative;
}

.group-3 {
    flex-shrink: 0;
    width: 1rem;
    height: 1rem;
    position: relative;
    overflow: visible;
}

.frame-9462 {
    display: flex;
    flex-direction: row;
    gap: 0.5rem;
    align-items: center;
    justify-content: flex-start;
    flex-shrink: 0;
    position: relative;
}

.efficacy {
    color: #2e2d2c;
    text-align: left;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 1rem;
    font-weight: 400;
    position: relative;
}

.group-32 {
    flex-shrink: 0;
    width: 1rem;
    height: 1rem;
    position: relative;
    overflow: visible;
}

.frame-947 {
    display: flex;
    flex-direction: row;
    gap: 0.5rem;
    align-items: center;
    justify-content: flex-start;
    flex-shrink: 0;
    position: relative;
}

.dosing-safety {
    color: #2e2d2c;
    text-align: left;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 1rem;
    font-weight: 400;
    position: relative;
}

.frame-9502 {
    display: flex;
    flex-direction: row;
    gap: 0.5rem;
    align-items: center;
    justify-content: flex-start;
    flex-shrink: 0;
    position: relative;
}

.why-soft-mist {
    color: #2e2d2c;
    text-align: left;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 1rem;
    font-weight: 400;
    position: relative;
}

.frame-949 {
    display: flex;
    flex-direction: row;
    gap: 0.5rem;
    align-items: center;
    justify-content: flex-start;
    flex-shrink: 0;
    position: relative;
}

.patient-support {
    color: #2e2d2c;
    text-align: left;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 1rem;
    font-weight: 400;
    position: relative;
}

.group-33 {
    flex-shrink: 0;
    width: 1rem;
    height: 1rem;
    position: relative;
    overflow: visible;
}

.group-857 {
    width: 7.125rem;
    height: 3.5625rem;
    position: static;
}

.rectangle-31 {
    background: linear-gradient( 90deg, rgba(25, 25, 25, 0) 0%, rgba(25, 25, 25, 0.25) 100% );
    width: 3.5625rem;
    height: 3.5625rem;
    position: absolute;
    left: 78.25rem;
    top: 16.3125rem;
}

.group-856 {
    width: 3.5625rem;
    height: 3.5625rem;
    position: static;
}

.rectangle-30 {
    background: #ffffff;
    width: 3.5625rem;
    height: 3.5625rem;
    position: absolute;
    left: 81.8125rem;
    top: 16.3125rem;
}

.group-2 {
    width: 1rem;
    height: 1rem;
    position: absolute;
    left: 83.09375rem;
    top: 17.59375rem;
    overflow: visible;
}

.line-29 {
    margin-top: -0.0625rem;
    border-style: solid;
    border-color: #08312a;
    border-width: 0.0625rem 0 0 0;
    width: 7rem;
    height: 0rem;
    position: absolute;
    left: 4.6875rem;
    top: 18.8125rem;
    display: none;
}

.rectangle-25 {
    background: #efeeeb;
    width: 100%; /*78rem;*/
    height: 3rem;
    position: absolute;
    left: 0rem;
    top: 7rem;
}

.logo {
    display: flex;
    flex-direction: row;
    gap: 0rem;
    align-items: center;
    justify-content: flex-start;
    width: 10rem;
    height: 5rem;
    position: absolute;
    left: 5rem;
    top: 6.2rem;
    object-fit: cover;
}

.group-1159 {
    position: absolute;
    inset: 0;
}

.samples-are-now-available-online {
    color: #08312a;
    text-align: left;
    font-family: "BoehringerForwardHead-Md", sans-serif;
    font-size: 1.75rem;
    line-height: 2.5rem;
    font-weight: 400;
    position: absolute;
    left: 33.1875rem;
    top: 42.711875rem;
    width: 27.25rem;
}

.request-samples-at-your-convenience-through-our-sample-closet-samples-allows-your-patients-to-initiate-new-therapy-quickly-and-easily-please-provide-your-name-and-npi-number-to-see-if-you-re-eligible {
    color: #191919;
    text-align: left;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 1.125rem;
    line-height: 1.5rem;
    font-weight: 400;
    position: absolute;
    left: 33.1875rem;
    top: 46.711875rem;
    width: 27.25rem;
}

.group-1146 {
    width: 25.25rem;
    height: 15.950625rem;
    position: static;
}

.group-1145 {
    width: 25.25rem;
    height: 15.950625rem;
    position: static;
}

.group-1144 {
    width: 25.25rem;
    height: 15.950625rem;
    position: static;
}

.rectangle-74 {
    background: #ffffff;
    width: 25.25rem;
    height: 15.9375rem;
    position: absolute;
    left: 4.701875rem;
    top: 42.6875rem;
}

.packshot-112095-021-spiriva-respimat-1 {
    width: 15.9375rem;
    height: 15.9375rem;
    position: absolute;
    left: 4.71375rem;
    top: 42.700625rem;
    object-fit: cover;
}

.vector-1 {
    width: 10.986875rem;
    height: 15.9375rem;
    position: absolute;
    left: 18.975rem;
    ;
    top: 42.6875rem;
    overflow: visible;
}

.vector-2 {
    width: 5.43375rem;
    height: 15.9375rem;
    position: absolute;
    left: 24.518125rem;
    top: 42.6875rem;
    overflow: visible;
}

.frame-963 {
    background: #00e47c;
    padding: 0.875rem 1.5rem 0.875rem 1.5rem;
    display: flex;
    flex-direction: row;
    gap: 0.75rem;
    align-items: center;
    justify-content: flex-start;
    height: 3rem;
    position: absolute;
    left: 33.1875rem;
    top: 55.711875rem;
}

.order-now {
    color: #08312a;
    text-align: left;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 1rem;
    font-weight: 400;
    position: relative;
}

.group-1 {
    flex-shrink: 0;
    width: 1rem;
    height: 1rem;
    position: relative;
    overflow: visible;
}

.frame-968 {
    display: flex;
    flex-direction: row;
    gap: 0.3125rem;
    align-items: center;
    justify-content: flex-start;
    height: 1rem;
    position: absolute;
    left: 4.6875rem;
    top: 60.149375rem;
}

.div {
    color: #000000;
    text-align: left;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 0.75rem;
    font-weight: 400;
    position: relative;
}

.terms-and-conditions-apply-government-restrictions-exclude-patients-enrolled-in-government-funded-programs-from-participating {
    color: #191919;
    text-align: left;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 0.75rem;
    font-weight: 400;
    position: relative;
}

.terms-and-conditions-apply-government-restrictions-exclude-patients-enrolled-in-government-funded-programs-from-participating-span {
    color: #191919;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 0.75rem;
    font-weight: 400;
    text-decoration: underline;
}

.terms-and-conditions-apply-government-restrictions-exclude-patients-enrolled-in-government-funded-programs-from-participating-span2 {
    color: #191919;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 0.75rem;
    font-weight: 400;
}

.vector2 {
    flex-shrink: 0;
    width: 0.5rem;
    height: 0.5rem;
    position: relative;
    overflow: visible;
}

.group-1133 {
    width: 17.5rem;
    height: 19.25rem;
    position: static;
}

.frame-983 {
    background: #e5e3de;
    padding: 1.5rem;
    display: flex;
    flex-direction: column;
    gap: 0.625rem;
    align-items: flex-start;
    justify-content: flex-start;
    width: 17.5rem;
    position: absolute;
    left: 63.1875rem;
    top: 45.4625rem;
}

.frame-982 {
    display: flex;
    flex-direction: column;
    gap: 0.75rem;
    align-items: flex-start;
    justify-content: flex-start;
    flex-shrink: 0;
    width: 14.5rem;
    position: relative;
}

.frame-981 {
    display: flex;
    flex-direction: row;
    gap: 0.75rem;
    align-items: center;
    justify-content: flex-start;
    align-self: stretch;
    flex-shrink: 0;
    position: relative;
}

.group-1125 {
    flex-shrink: 0;
    width: 1.25rem;
    height: 1.25rem;
    position: relative;
    overflow: visible;
}

.lama-treatment2 {
    color: #2e2d2c;
    text-align: left;
    font-family: "BoehringerForwardText-Md", sans-serif;
    font-size: 1.1875rem;
    line-height: 1.75rem;
    font-weight: 400;
    position: relative;
    width: 12.5rem;
}

.frame-9822 {
    display: flex;
    flex-direction: row;
    gap: 0.75rem;
    align-items: center;
    justify-content: flex-start;
    align-self: stretch;
    flex-shrink: 0;
    position: relative;
}

.group-11252 {
    flex-shrink: 0;
    width: 1.25rem;
    height: 1.25rem;
    position: relative;
    overflow: visible;
}

.efficacy2 {
    color: #2e2d2c;
    text-align: left;
    font-family: "BoehringerForwardText-Md", sans-serif;
    font-size: 1.1875rem;
    line-height: 1.75rem;
    font-weight: 400;
    position: relative;
    width: 12.5rem;
}

.frame-9832 {
    display: flex;
    flex-direction: row;
    gap: 0.75rem;
    align-items: center;
    justify-content: flex-start;
    align-self: stretch;
    flex-shrink: 0;
    position: relative;
}

.group-11253 {
    flex-shrink: 0;
    width: 1.25rem;
    height: 1.25rem;
    position: relative;
    overflow: visible;
}

.dosing-safety2 {
    color: #2e2d2c;
    text-align: left;
    font-family: "BoehringerForwardText-Md", sans-serif;
    font-size: 1.1875rem;
    line-height: 1.75rem;
    font-weight: 400;
    position: relative;
    width: 12.5rem;
}

.frame-984 {
    display: flex;
    flex-direction: row;
    gap: 0.75rem;
    align-items: center;
    justify-content: flex-start;
    align-self: stretch;
    flex-shrink: 0;
    position: relative;
}

.group-11254 {
    flex-shrink: 0;
    width: 1.25rem;
    height: 1.25rem;
    position: relative;
    overflow: visible;
}

.request-savings-card {
    color: #2e2d2c;
    text-align: left;
    font-family: "BoehringerForwardText-Md", sans-serif;
    font-size: 1.1875rem;
    line-height: 1.75rem;
    font-weight: 400;
    position: relative;
    width: 12.5rem;
}

.frame-980 {
    display: flex;
    flex-direction: row;
    gap: 0.75rem;
    align-items: center;
    justify-content: flex-start;
    align-self: stretch;
    flex-shrink: 0;
    position: relative;
}

.group-1126 {
    flex-shrink: 0;
    width: 1.25rem;
    height: 1.25rem;
    position: relative;
    overflow: visible;
}

.respimat-quick-start-guide {
    color: #2e2d2c;
    text-align: left;
    font-family: "BoehringerForwardText-Md", sans-serif;
    font-size: 1.1875rem;
    line-height: 1.75rem;
    font-weight: 400;
    position: relative;
    width: 11.8125rem;
}

.quick-links {
    color: #2e2d2c;
    text-align: left;
    font-family: "BoehringerForwardText-Md", sans-serif;
    font-size: 1.4375rem;
    line-height: 1.75rem;
    font-weight: 400;
    position: absolute;
    left: 63.1875rem;
    top: 42.711875rem;
}

.group-1160 {
    position: absolute;
    inset: 0;
}

.group-884 {
    width: 78rem;
    height: 82rem;
    position: static;
}

.group-883 {
    width: 78rem;
    height: 82rem;
    position: static;
}

.group-881 {
    width: 78rem;
    height: 58.25rem;
    position: static;
}

.rectangle-36 {
    background: #ffffff;
    width: 78rem;
    height: 58.25rem;
    position: absolute;
    left: 0rem;
    top: 67.5rem;
}

.group-880 {
    width: 76rem;
    height: 55.25rem;
    position: static;
}

.frame-951 {
    display: flex;
    flex-direction: column;
    gap: 1rem;
    align-items: flex-start;
    justify-content: flex-start;
    width: 36rem;
    position: absolute;
    left: 4.6875rem;
    top: 68.5rem;
}

.important-safety-information {
    color: #191919;
    text-align: left;
    font-family: "BoehringerForwardText-Md", sans-serif;
    font-size: 1.1875rem;
    line-height: 1.75rem;
    font-weight: 400;
    position: relative;
    align-self: stretch;
}

.spiriva-respimat-tiotropium-bromide-inhalation-spray-is-contraindicated-in-patients-with-a-hypersensitivity-to-tiotropium-ipratropium-or-any-component-of-this-product-immediate-hypersensitivity-reactions-including-angioedema-including-swelling-of-the-lips-tongue-or-throat-itching-or-rash-have-been-reported {
    color: #191919;
    text-align: left;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 1rem;
    line-height: 1.5rem;
    font-weight: 400;
    position: relative;
    align-self: stretch;
}

.frame-952 {
    display: flex;
    flex-direction: column;
    gap: 1rem;
    align-items: flex-start;
    justify-content: flex-start;
    width: 76rem;
    position: absolute;
    left: 4.6875rem;
    top: 79.25rem;
}

.spiriva-respimat-is-intended-as-a-once-daily-maintenance-treatment-for-asthma-and-should-not-be-used-for-the-relief-of-acute-symptoms-i-e-as-rescue-therapy-for-the-treatment-of-acute-episodes-of-bronchospasm-in-the-event-of-an-attack-a-rapid-acting-beta-2-agonist-should-be-used-immediate-hypersensitivity-reactions-including-urticaria-angioedema-including-swelling-of-the-lips-tongue-or-throat-rash-bronchospasm-anaphylaxis-or-itching-may-occur-after-administration-of-spiriva-respimat-if-such-a-reaction-occurs-discontinue-spiriva-respimat-at-once-and-consider-alternative-treatments-given-the-similar-structural-formula-of-atropine-to-tiotropium-patients-with-a-history-of-hypersensitivity-reactions-to-atropine-or-its-derivatives-should-be-closely-monitored-for-similar-hypersensitivity-reactions-to-spiriva-respimat-inhaled-medicines-including-spiriva-respimat-may-cause-paradoxical-bronchospasm-if-this-occurs-it-should-be-treated-with-an-inhaled-short-acting-beta-2-agonist-such-as-albuterol-treatment-with-spiriva-respimat-should-be-stopped-and-other-treatments-considered-spiriva-respimat-should-be-used-with-caution-in-patients-with-narrow-angle-glaucoma-prescribers-and-patients-should-be-alert-for-signs-and-symptoms-of-acute-narrow-angle-glaucoma-e-g-eye-pain-or-discomfort-blurred-vision-visual-halos-or-colored-images-in-association-with-red-eyes-from-conjunctival-congestion-and-corneal-edema-instruct-patients-to-consult-a-physician-immediately-should-any-of-these-signs-or-symptoms-develop-since-dizziness-and-blurred-vision-may-occur-with-the-use-of-spiriva-respimat-caution-patients-about-engaging-in-activities-such-as-driving-a-vehicle-or-operating-appliances-or-machinery-spiriva-respimat-should-be-used-with-caution-in-patients-with-urinary-retention-prescribers-and-patients-should-be-alert-for-signs-and-symptoms-of-urinary-retention-e-g-difficulty-passing-urine-painful-urination-especially-in-patients-with-prostatic-hyperplasia-or-bladder-neck-obstruction-instruct-patients-to-consult-a-physician-immediately-should-any-of-these-signs-or-symptoms-develop-patients-with-moderate-to-severe-renal-impairment-creatinine-clearance-of-60-m-l-min-treated-with-spiriva-respimat-should-be-monitored-closely-for-anticholinergic-side-effects-the-most-common-adverse-reactions-2-incidence-and-higher-than-placebo-with-spiriva-respimat-placebo-in-asthma-trials-in-adults-were-pharyngitis-15-9-12-4-headache-3-8-2-7-bronchitis-3-3-1-4-and-sinusitis-2-7-1-4-the-adverse-reaction-profile-for-adolescent-and-pediatric-patients-was-comparable-to-that-observed-in-adult-patients-with-asthma-spiriva-respimat-may-interact-additively-with-concomitantly-used-anticholinergic-medications-avoid-administration-of-spiriva-respimat-with-other-anticholinergic-containing-drugs-inform-patients-not-to-spray-spiriva-respimat-into-the-eyes-as-this-may-cause-blurring-of-vision-and-pupil-dilation-please-see-full-prescribing-information-including-instructions-for-use-for-spiriva-respimat-cl-svr-0044-2-15-2017 {
    color: #191919;
    text-align: left;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 1rem;
    line-height: 1.5rem;
    font-weight: 400;
    position: relative;
    width: 76rem;
}

.spiriva-respimat-is-intended-as-a-once-daily-maintenance-treatment-for-asthma-and-should-not-be-used-for-the-relief-of-acute-symptoms-i-e-as-rescue-therapy-for-the-treatment-of-acute-episodes-of-bronchospasm-in-the-event-of-an-attack-a-rapid-acting-beta-2-agonist-should-be-used-immediate-hypersensitivity-reactions-including-urticaria-angioedema-including-swelling-of-the-lips-tongue-or-throat-rash-bronchospasm-anaphylaxis-or-itching-may-occur-after-administration-of-spiriva-respimat-if-such-a-reaction-occurs-discontinue-spiriva-respimat-at-once-and-consider-alternative-treatments-given-the-similar-structural-formula-of-atropine-to-tiotropium-patients-with-a-history-of-hypersensitivity-reactions-to-atropine-or-its-derivatives-should-be-closely-monitored-for-similar-hypersensitivity-reactions-to-spiriva-respimat-inhaled-medicines-including-spiriva-respimat-may-cause-paradoxical-bronchospasm-if-this-occurs-it-should-be-treated-with-an-inhaled-short-acting-beta-2-agonist-such-as-albuterol-treatment-with-spiriva-respimat-should-be-stopped-and-other-treatments-considered-spiriva-respimat-should-be-used-with-caution-in-patients-with-narrow-angle-glaucoma-prescribers-and-patients-should-be-alert-for-signs-and-symptoms-of-acute-narrow-angle-glaucoma-e-g-eye-pain-or-discomfort-blurred-vision-visual-halos-or-colored-images-in-association-with-red-eyes-from-conjunctival-congestion-and-corneal-edema-instruct-patients-to-consult-a-physician-immediately-should-any-of-these-signs-or-symptoms-develop-since-dizziness-and-blurred-vision-may-occur-with-the-use-of-spiriva-respimat-caution-patients-about-engaging-in-activities-such-as-driving-a-vehicle-or-operating-appliances-or-machinery-spiriva-respimat-should-be-used-with-caution-in-patients-with-urinary-retention-prescribers-and-patients-should-be-alert-for-signs-and-symptoms-of-urinary-retention-e-g-difficulty-passing-urine-painful-urination-especially-in-patients-with-prostatic-hyperplasia-or-bladder-neck-obstruction-instruct-patients-to-consult-a-physician-immediately-should-any-of-these-signs-or-symptoms-develop-patients-with-moderate-to-severe-renal-impairment-creatinine-clearance-of-60-m-l-min-treated-with-spiriva-respimat-should-be-monitored-closely-for-anticholinergic-side-effects-the-most-common-adverse-reactions-2-incidence-and-higher-than-placebo-with-spiriva-respimat-placebo-in-asthma-trials-in-adults-were-pharyngitis-15-9-12-4-headache-3-8-2-7-bronchitis-3-3-1-4-and-sinusitis-2-7-1-4-the-adverse-reaction-profile-for-adolescent-and-pediatric-patients-was-comparable-to-that-observed-in-adult-patients-with-asthma-spiriva-respimat-may-interact-additively-with-concomitantly-used-anticholinergic-medications-avoid-administration-of-spiriva-respimat-with-other-anticholinergic-containing-drugs-inform-patients-not-to-spray-spiriva-respimat-into-the-eyes-as-this-may-cause-blurring-of-vision-and-pupil-dilation-please-see-full-prescribing-information-including-instructions-for-use-for-spiriva-respimat-cl-svr-0044-2-15-2017-span {
    color: #191919;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 1rem;
    line-height: 1.5rem;
    font-weight: 400;
}

.spiriva-respimat-is-intended-as-a-once-daily-maintenance-treatment-for-asthma-and-should-not-be-used-for-the-relief-of-acute-symptoms-i-e-as-rescue-therapy-for-the-treatment-of-acute-episodes-of-bronchospasm-in-the-event-of-an-attack-a-rapid-acting-beta-2-agonist-should-be-used-immediate-hypersensitivity-reactions-including-urticaria-angioedema-including-swelling-of-the-lips-tongue-or-throat-rash-bronchospasm-anaphylaxis-or-itching-may-occur-after-administration-of-spiriva-respimat-if-such-a-reaction-occurs-discontinue-spiriva-respimat-at-once-and-consider-alternative-treatments-given-the-similar-structural-formula-of-atropine-to-tiotropium-patients-with-a-history-of-hypersensitivity-reactions-to-atropine-or-its-derivatives-should-be-closely-monitored-for-similar-hypersensitivity-reactions-to-spiriva-respimat-inhaled-medicines-including-spiriva-respimat-may-cause-paradoxical-bronchospasm-if-this-occurs-it-should-be-treated-with-an-inhaled-short-acting-beta-2-agonist-such-as-albuterol-treatment-with-spiriva-respimat-should-be-stopped-and-other-treatments-considered-spiriva-respimat-should-be-used-with-caution-in-patients-with-narrow-angle-glaucoma-prescribers-and-patients-should-be-alert-for-signs-and-symptoms-of-acute-narrow-angle-glaucoma-e-g-eye-pain-or-discomfort-blurred-vision-visual-halos-or-colored-images-in-association-with-red-eyes-from-conjunctival-congestion-and-corneal-edema-instruct-patients-to-consult-a-physician-immediately-should-any-of-these-signs-or-symptoms-develop-since-dizziness-and-blurred-vision-may-occur-with-the-use-of-spiriva-respimat-caution-patients-about-engaging-in-activities-such-as-driving-a-vehicle-or-operating-appliances-or-machinery-spiriva-respimat-should-be-used-with-caution-in-patients-with-urinary-retention-prescribers-and-patients-should-be-alert-for-signs-and-symptoms-of-urinary-retention-e-g-difficulty-passing-urine-painful-urination-especially-in-patients-with-prostatic-hyperplasia-or-bladder-neck-obstruction-instruct-patients-to-consult-a-physician-immediately-should-any-of-these-signs-or-symptoms-develop-patients-with-moderate-to-severe-renal-impairment-creatinine-clearance-of-60-m-l-min-treated-with-spiriva-respimat-should-be-monitored-closely-for-anticholinergic-side-effects-the-most-common-adverse-reactions-2-incidence-and-higher-than-placebo-with-spiriva-respimat-placebo-in-asthma-trials-in-adults-were-pharyngitis-15-9-12-4-headache-3-8-2-7-bronchitis-3-3-1-4-and-sinusitis-2-7-1-4-the-adverse-reaction-profile-for-adolescent-and-pediatric-patients-was-comparable-to-that-observed-in-adult-patients-with-asthma-spiriva-respimat-may-interact-additively-with-concomitantly-used-anticholinergic-medications-avoid-administration-of-spiriva-respimat-with-other-anticholinergic-containing-drugs-inform-patients-not-to-spray-spiriva-respimat-into-the-eyes-as-this-may-cause-blurring-of-vision-and-pupil-dilation-please-see-full-prescribing-information-including-instructions-for-use-for-spiriva-respimat-cl-svr-0044-2-15-2017-span2 {
    color: #191919;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 1rem;
    line-height: 1.5rem;
    font-weight: 400;
}

.spiriva-respimat-is-intended-as-a-once-daily-maintenance-treatment-for-asthma-and-should-not-be-used-for-the-relief-of-acute-symptoms-i-e-as-rescue-therapy-for-the-treatment-of-acute-episodes-of-bronchospasm-in-the-event-of-an-attack-a-rapid-acting-beta-2-agonist-should-be-used-immediate-hypersensitivity-reactions-including-urticaria-angioedema-including-swelling-of-the-lips-tongue-or-throat-rash-bronchospasm-anaphylaxis-or-itching-may-occur-after-administration-of-spiriva-respimat-if-such-a-reaction-occurs-discontinue-spiriva-respimat-at-once-and-consider-alternative-treatments-given-the-similar-structural-formula-of-atropine-to-tiotropium-patients-with-a-history-of-hypersensitivity-reactions-to-atropine-or-its-derivatives-should-be-closely-monitored-for-similar-hypersensitivity-reactions-to-spiriva-respimat-inhaled-medicines-including-spiriva-respimat-may-cause-paradoxical-bronchospasm-if-this-occurs-it-should-be-treated-with-an-inhaled-short-acting-beta-2-agonist-such-as-albuterol-treatment-with-spiriva-respimat-should-be-stopped-and-other-treatments-considered-spiriva-respimat-should-be-used-with-caution-in-patients-with-narrow-angle-glaucoma-prescribers-and-patients-should-be-alert-for-signs-and-symptoms-of-acute-narrow-angle-glaucoma-e-g-eye-pain-or-discomfort-blurred-vision-visual-halos-or-colored-images-in-association-with-red-eyes-from-conjunctival-congestion-and-corneal-edema-instruct-patients-to-consult-a-physician-immediately-should-any-of-these-signs-or-symptoms-develop-since-dizziness-and-blurred-vision-may-occur-with-the-use-of-spiriva-respimat-caution-patients-about-engaging-in-activities-such-as-driving-a-vehicle-or-operating-appliances-or-machinery-spiriva-respimat-should-be-used-with-caution-in-patients-with-urinary-retention-prescribers-and-patients-should-be-alert-for-signs-and-symptoms-of-urinary-retention-e-g-difficulty-passing-urine-painful-urination-especially-in-patients-with-prostatic-hyperplasia-or-bladder-neck-obstruction-instruct-patients-to-consult-a-physician-immediately-should-any-of-these-signs-or-symptoms-develop-patients-with-moderate-to-severe-renal-impairment-creatinine-clearance-of-60-m-l-min-treated-with-spiriva-respimat-should-be-monitored-closely-for-anticholinergic-side-effects-the-most-common-adverse-reactions-2-incidence-and-higher-than-placebo-with-spiriva-respimat-placebo-in-asthma-trials-in-adults-were-pharyngitis-15-9-12-4-headache-3-8-2-7-bronchitis-3-3-1-4-and-sinusitis-2-7-1-4-the-adverse-reaction-profile-for-adolescent-and-pediatric-patients-was-comparable-to-that-observed-in-adult-patients-with-asthma-spiriva-respimat-may-interact-additively-with-concomitantly-used-anticholinergic-medications-avoid-administration-of-spiriva-respimat-with-other-anticholinergic-containing-drugs-inform-patients-not-to-spray-spiriva-respimat-into-the-eyes-as-this-may-cause-blurring-of-vision-and-pupil-dilation-please-see-full-prescribing-information-including-instructions-for-use-for-spiriva-respimat-cl-svr-0044-2-15-2017-span3 {
    color: #191919;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 1rem;
    line-height: 1.5rem;
    font-weight: 400;
}

.spiriva-respimat-is-intended-as-a-once-daily-maintenance-treatment-for-asthma-and-should-not-be-used-for-the-relief-of-acute-symptoms-i-e-as-rescue-therapy-for-the-treatment-of-acute-episodes-of-bronchospasm-in-the-event-of-an-attack-a-rapid-acting-beta-2-agonist-should-be-used-immediate-hypersensitivity-reactions-including-urticaria-angioedema-including-swelling-of-the-lips-tongue-or-throat-rash-bronchospasm-anaphylaxis-or-itching-may-occur-after-administration-of-spiriva-respimat-if-such-a-reaction-occurs-discontinue-spiriva-respimat-at-once-and-consider-alternative-treatments-given-the-similar-structural-formula-of-atropine-to-tiotropium-patients-with-a-history-of-hypersensitivity-reactions-to-atropine-or-its-derivatives-should-be-closely-monitored-for-similar-hypersensitivity-reactions-to-spiriva-respimat-inhaled-medicines-including-spiriva-respimat-may-cause-paradoxical-bronchospasm-if-this-occurs-it-should-be-treated-with-an-inhaled-short-acting-beta-2-agonist-such-as-albuterol-treatment-with-spiriva-respimat-should-be-stopped-and-other-treatments-considered-spiriva-respimat-should-be-used-with-caution-in-patients-with-narrow-angle-glaucoma-prescribers-and-patients-should-be-alert-for-signs-and-symptoms-of-acute-narrow-angle-glaucoma-e-g-eye-pain-or-discomfort-blurred-vision-visual-halos-or-colored-images-in-association-with-red-eyes-from-conjunctival-congestion-and-corneal-edema-instruct-patients-to-consult-a-physician-immediately-should-any-of-these-signs-or-symptoms-develop-since-dizziness-and-blurred-vision-may-occur-with-the-use-of-spiriva-respimat-caution-patients-about-engaging-in-activities-such-as-driving-a-vehicle-or-operating-appliances-or-machinery-spiriva-respimat-should-be-used-with-caution-in-patients-with-urinary-retention-prescribers-and-patients-should-be-alert-for-signs-and-symptoms-of-urinary-retention-e-g-difficulty-passing-urine-painful-urination-especially-in-patients-with-prostatic-hyperplasia-or-bladder-neck-obstruction-instruct-patients-to-consult-a-physician-immediately-should-any-of-these-signs-or-symptoms-develop-patients-with-moderate-to-severe-renal-impairment-creatinine-clearance-of-60-m-l-min-treated-with-spiriva-respimat-should-be-monitored-closely-for-anticholinergic-side-effects-the-most-common-adverse-reactions-2-incidence-and-higher-than-placebo-with-spiriva-respimat-placebo-in-asthma-trials-in-adults-were-pharyngitis-15-9-12-4-headache-3-8-2-7-bronchitis-3-3-1-4-and-sinusitis-2-7-1-4-the-adverse-reaction-profile-for-adolescent-and-pediatric-patients-was-comparable-to-that-observed-in-adult-patients-with-asthma-spiriva-respimat-may-interact-additively-with-concomitantly-used-anticholinergic-medications-avoid-administration-of-spiriva-respimat-with-other-anticholinergic-containing-drugs-inform-patients-not-to-spray-spiriva-respimat-into-the-eyes-as-this-may-cause-blurring-of-vision-and-pupil-dilation-please-see-full-prescribing-information-including-instructions-for-use-for-spiriva-respimat-cl-svr-0044-2-15-2017-span4 {
    color: #191919;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 1rem;
    line-height: 1.5rem;
    font-weight: 400;
}

.spiriva-respimat-is-intended-as-a-once-daily-maintenance-treatment-for-asthma-and-should-not-be-used-for-the-relief-of-acute-symptoms-i-e-as-rescue-therapy-for-the-treatment-of-acute-episodes-of-bronchospasm-in-the-event-of-an-attack-a-rapid-acting-beta-2-agonist-should-be-used-immediate-hypersensitivity-reactions-including-urticaria-angioedema-including-swelling-of-the-lips-tongue-or-throat-rash-bronchospasm-anaphylaxis-or-itching-may-occur-after-administration-of-spiriva-respimat-if-such-a-reaction-occurs-discontinue-spiriva-respimat-at-once-and-consider-alternative-treatments-given-the-similar-structural-formula-of-atropine-to-tiotropium-patients-with-a-history-of-hypersensitivity-reactions-to-atropine-or-its-derivatives-should-be-closely-monitored-for-similar-hypersensitivity-reactions-to-spiriva-respimat-inhaled-medicines-including-spiriva-respimat-may-cause-paradoxical-bronchospasm-if-this-occurs-it-should-be-treated-with-an-inhaled-short-acting-beta-2-agonist-such-as-albuterol-treatment-with-spiriva-respimat-should-be-stopped-and-other-treatments-considered-spiriva-respimat-should-be-used-with-caution-in-patients-with-narrow-angle-glaucoma-prescribers-and-patients-should-be-alert-for-signs-and-symptoms-of-acute-narrow-angle-glaucoma-e-g-eye-pain-or-discomfort-blurred-vision-visual-halos-or-colored-images-in-association-with-red-eyes-from-conjunctival-congestion-and-corneal-edema-instruct-patients-to-consult-a-physician-immediately-should-any-of-these-signs-or-symptoms-develop-since-dizziness-and-blurred-vision-may-occur-with-the-use-of-spiriva-respimat-caution-patients-about-engaging-in-activities-such-as-driving-a-vehicle-or-operating-appliances-or-machinery-spiriva-respimat-should-be-used-with-caution-in-patients-with-urinary-retention-prescribers-and-patients-should-be-alert-for-signs-and-symptoms-of-urinary-retention-e-g-difficulty-passing-urine-painful-urination-especially-in-patients-with-prostatic-hyperplasia-or-bladder-neck-obstruction-instruct-patients-to-consult-a-physician-immediately-should-any-of-these-signs-or-symptoms-develop-patients-with-moderate-to-severe-renal-impairment-creatinine-clearance-of-60-m-l-min-treated-with-spiriva-respimat-should-be-monitored-closely-for-anticholinergic-side-effects-the-most-common-adverse-reactions-2-incidence-and-higher-than-placebo-with-spiriva-respimat-placebo-in-asthma-trials-in-adults-were-pharyngitis-15-9-12-4-headache-3-8-2-7-bronchitis-3-3-1-4-and-sinusitis-2-7-1-4-the-adverse-reaction-profile-for-adolescent-and-pediatric-patients-was-comparable-to-that-observed-in-adult-patients-with-asthma-spiriva-respimat-may-interact-additively-with-concomitantly-used-anticholinergic-medications-avoid-administration-of-spiriva-respimat-with-other-anticholinergic-containing-drugs-inform-patients-not-to-spray-spiriva-respimat-into-the-eyes-as-this-may-cause-blurring-of-vision-and-pupil-dilation-please-see-full-prescribing-information-including-instructions-for-use-for-spiriva-respimat-cl-svr-0044-2-15-2017-span5 {
    color: #191919;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 1rem;
    line-height: 1.5rem;
    font-weight: 400;
}

.spiriva-respimat-is-intended-as-a-once-daily-maintenance-treatment-for-asthma-and-should-not-be-used-for-the-relief-of-acute-symptoms-i-e-as-rescue-therapy-for-the-treatment-of-acute-episodes-of-bronchospasm-in-the-event-of-an-attack-a-rapid-acting-beta-2-agonist-should-be-used-immediate-hypersensitivity-reactions-including-urticaria-angioedema-including-swelling-of-the-lips-tongue-or-throat-rash-bronchospasm-anaphylaxis-or-itching-may-occur-after-administration-of-spiriva-respimat-if-such-a-reaction-occurs-discontinue-spiriva-respimat-at-once-and-consider-alternative-treatments-given-the-similar-structural-formula-of-atropine-to-tiotropium-patients-with-a-history-of-hypersensitivity-reactions-to-atropine-or-its-derivatives-should-be-closely-monitored-for-similar-hypersensitivity-reactions-to-spiriva-respimat-inhaled-medicines-including-spiriva-respimat-may-cause-paradoxical-bronchospasm-if-this-occurs-it-should-be-treated-with-an-inhaled-short-acting-beta-2-agonist-such-as-albuterol-treatment-with-spiriva-respimat-should-be-stopped-and-other-treatments-considered-spiriva-respimat-should-be-used-with-caution-in-patients-with-narrow-angle-glaucoma-prescribers-and-patients-should-be-alert-for-signs-and-symptoms-of-acute-narrow-angle-glaucoma-e-g-eye-pain-or-discomfort-blurred-vision-visual-halos-or-colored-images-in-association-with-red-eyes-from-conjunctival-congestion-and-corneal-edema-instruct-patients-to-consult-a-physician-immediately-should-any-of-these-signs-or-symptoms-develop-since-dizziness-and-blurred-vision-may-occur-with-the-use-of-spiriva-respimat-caution-patients-about-engaging-in-activities-such-as-driving-a-vehicle-or-operating-appliances-or-machinery-spiriva-respimat-should-be-used-with-caution-in-patients-with-urinary-retention-prescribers-and-patients-should-be-alert-for-signs-and-symptoms-of-urinary-retention-e-g-difficulty-passing-urine-painful-urination-especially-in-patients-with-prostatic-hyperplasia-or-bladder-neck-obstruction-instruct-patients-to-consult-a-physician-immediately-should-any-of-these-signs-or-symptoms-develop-patients-with-moderate-to-severe-renal-impairment-creatinine-clearance-of-60-m-l-min-treated-with-spiriva-respimat-should-be-monitored-closely-for-anticholinergic-side-effects-the-most-common-adverse-reactions-2-incidence-and-higher-than-placebo-with-spiriva-respimat-placebo-in-asthma-trials-in-adults-were-pharyngitis-15-9-12-4-headache-3-8-2-7-bronchitis-3-3-1-4-and-sinusitis-2-7-1-4-the-adverse-reaction-profile-for-adolescent-and-pediatric-patients-was-comparable-to-that-observed-in-adult-patients-with-asthma-spiriva-respimat-may-interact-additively-with-concomitantly-used-anticholinergic-medications-avoid-administration-of-spiriva-respimat-with-other-anticholinergic-containing-drugs-inform-patients-not-to-spray-spiriva-respimat-into-the-eyes-as-this-may-cause-blurring-of-vision-and-pupil-dilation-please-see-full-prescribing-information-including-instructions-for-use-for-spiriva-respimat-cl-svr-0044-2-15-2017-span6 {
    color: #191919;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 1rem;
    line-height: 1.5rem;
    font-weight: 400;
    text-decoration: underline;
}

.spiriva-respimat-is-intended-as-a-once-daily-maintenance-treatment-for-asthma-and-should-not-be-used-for-the-relief-of-acute-symptoms-i-e-as-rescue-therapy-for-the-treatment-of-acute-episodes-of-bronchospasm-in-the-event-of-an-attack-a-rapid-acting-beta-2-agonist-should-be-used-immediate-hypersensitivity-reactions-including-urticaria-angioedema-including-swelling-of-the-lips-tongue-or-throat-rash-bronchospasm-anaphylaxis-or-itching-may-occur-after-administration-of-spiriva-respimat-if-such-a-reaction-occurs-discontinue-spiriva-respimat-at-once-and-consider-alternative-treatments-given-the-similar-structural-formula-of-atropine-to-tiotropium-patients-with-a-history-of-hypersensitivity-reactions-to-atropine-or-its-derivatives-should-be-closely-monitored-for-similar-hypersensitivity-reactions-to-spiriva-respimat-inhaled-medicines-including-spiriva-respimat-may-cause-paradoxical-bronchospasm-if-this-occurs-it-should-be-treated-with-an-inhaled-short-acting-beta-2-agonist-such-as-albuterol-treatment-with-spiriva-respimat-should-be-stopped-and-other-treatments-considered-spiriva-respimat-should-be-used-with-caution-in-patients-with-narrow-angle-glaucoma-prescribers-and-patients-should-be-alert-for-signs-and-symptoms-of-acute-narrow-angle-glaucoma-e-g-eye-pain-or-discomfort-blurred-vision-visual-halos-or-colored-images-in-association-with-red-eyes-from-conjunctival-congestion-and-corneal-edema-instruct-patients-to-consult-a-physician-immediately-should-any-of-these-signs-or-symptoms-develop-since-dizziness-and-blurred-vision-may-occur-with-the-use-of-spiriva-respimat-caution-patients-about-engaging-in-activities-such-as-driving-a-vehicle-or-operating-appliances-or-machinery-spiriva-respimat-should-be-used-with-caution-in-patients-with-urinary-retention-prescribers-and-patients-should-be-alert-for-signs-and-symptoms-of-urinary-retention-e-g-difficulty-passing-urine-painful-urination-especially-in-patients-with-prostatic-hyperplasia-or-bladder-neck-obstruction-instruct-patients-to-consult-a-physician-immediately-should-any-of-these-signs-or-symptoms-develop-patients-with-moderate-to-severe-renal-impairment-creatinine-clearance-of-60-m-l-min-treated-with-spiriva-respimat-should-be-monitored-closely-for-anticholinergic-side-effects-the-most-common-adverse-reactions-2-incidence-and-higher-than-placebo-with-spiriva-respimat-placebo-in-asthma-trials-in-adults-were-pharyngitis-15-9-12-4-headache-3-8-2-7-bronchitis-3-3-1-4-and-sinusitis-2-7-1-4-the-adverse-reaction-profile-for-adolescent-and-pediatric-patients-was-comparable-to-that-observed-in-adult-patients-with-asthma-spiriva-respimat-may-interact-additively-with-concomitantly-used-anticholinergic-medications-avoid-administration-of-spiriva-respimat-with-other-anticholinergic-containing-drugs-inform-patients-not-to-spray-spiriva-respimat-into-the-eyes-as-this-may-cause-blurring-of-vision-and-pupil-dilation-please-see-full-prescribing-information-including-instructions-for-use-for-spiriva-respimat-cl-svr-0044-2-15-2017-span7 {
    color: #191919;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 1rem;
    line-height: 1.5rem;
    font-weight: 400;
}

.spiriva-respimat-is-intended-as-a-once-daily-maintenance-treatment-for-asthma-and-should-not-be-used-for-the-relief-of-acute-symptoms-i-e-as-rescue-therapy-for-the-treatment-of-acute-episodes-of-bronchospasm-in-the-event-of-an-attack-a-rapid-acting-beta-2-agonist-should-be-used-immediate-hypersensitivity-reactions-including-urticaria-angioedema-including-swelling-of-the-lips-tongue-or-throat-rash-bronchospasm-anaphylaxis-or-itching-may-occur-after-administration-of-spiriva-respimat-if-such-a-reaction-occurs-discontinue-spiriva-respimat-at-once-and-consider-alternative-treatments-given-the-similar-structural-formula-of-atropine-to-tiotropium-patients-with-a-history-of-hypersensitivity-reactions-to-atropine-or-its-derivatives-should-be-closely-monitored-for-similar-hypersensitivity-reactions-to-spiriva-respimat-inhaled-medicines-including-spiriva-respimat-may-cause-paradoxical-bronchospasm-if-this-occurs-it-should-be-treated-with-an-inhaled-short-acting-beta-2-agonist-such-as-albuterol-treatment-with-spiriva-respimat-should-be-stopped-and-other-treatments-considered-spiriva-respimat-should-be-used-with-caution-in-patients-with-narrow-angle-glaucoma-prescribers-and-patients-should-be-alert-for-signs-and-symptoms-of-acute-narrow-angle-glaucoma-e-g-eye-pain-or-discomfort-blurred-vision-visual-halos-or-colored-images-in-association-with-red-eyes-from-conjunctival-congestion-and-corneal-edema-instruct-patients-to-consult-a-physician-immediately-should-any-of-these-signs-or-symptoms-develop-since-dizziness-and-blurred-vision-may-occur-with-the-use-of-spiriva-respimat-caution-patients-about-engaging-in-activities-such-as-driving-a-vehicle-or-operating-appliances-or-machinery-spiriva-respimat-should-be-used-with-caution-in-patients-with-urinary-retention-prescribers-and-patients-should-be-alert-for-signs-and-symptoms-of-urinary-retention-e-g-difficulty-passing-urine-painful-urination-especially-in-patients-with-prostatic-hyperplasia-or-bladder-neck-obstruction-instruct-patients-to-consult-a-physician-immediately-should-any-of-these-signs-or-symptoms-develop-patients-with-moderate-to-severe-renal-impairment-creatinine-clearance-of-60-m-l-min-treated-with-spiriva-respimat-should-be-monitored-closely-for-anticholinergic-side-effects-the-most-common-adverse-reactions-2-incidence-and-higher-than-placebo-with-spiriva-respimat-placebo-in-asthma-trials-in-adults-were-pharyngitis-15-9-12-4-headache-3-8-2-7-bronchitis-3-3-1-4-and-sinusitis-2-7-1-4-the-adverse-reaction-profile-for-adolescent-and-pediatric-patients-was-comparable-to-that-observed-in-adult-patients-with-asthma-spiriva-respimat-may-interact-additively-with-concomitantly-used-anticholinergic-medications-avoid-administration-of-spiriva-respimat-with-other-anticholinergic-containing-drugs-inform-patients-not-to-spray-spiriva-respimat-into-the-eyes-as-this-may-cause-blurring-of-vision-and-pupil-dilation-please-see-full-prescribing-information-including-instructions-for-use-for-spiriva-respimat-cl-svr-0044-2-15-2017-span8 {
    color: #191919;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 1rem;
    line-height: 1.5rem;
    font-weight: 400;
    text-decoration: underline;
}

.spiriva-respimat-is-intended-as-a-once-daily-maintenance-treatment-for-asthma-and-should-not-be-used-for-the-relief-of-acute-symptoms-i-e-as-rescue-therapy-for-the-treatment-of-acute-episodes-of-bronchospasm-in-the-event-of-an-attack-a-rapid-acting-beta-2-agonist-should-be-used-immediate-hypersensitivity-reactions-including-urticaria-angioedema-including-swelling-of-the-lips-tongue-or-throat-rash-bronchospasm-anaphylaxis-or-itching-may-occur-after-administration-of-spiriva-respimat-if-such-a-reaction-occurs-discontinue-spiriva-respimat-at-once-and-consider-alternative-treatments-given-the-similar-structural-formula-of-atropine-to-tiotropium-patients-with-a-history-of-hypersensitivity-reactions-to-atropine-or-its-derivatives-should-be-closely-monitored-for-similar-hypersensitivity-reactions-to-spiriva-respimat-inhaled-medicines-including-spiriva-respimat-may-cause-paradoxical-bronchospasm-if-this-occurs-it-should-be-treated-with-an-inhaled-short-acting-beta-2-agonist-such-as-albuterol-treatment-with-spiriva-respimat-should-be-stopped-and-other-treatments-considered-spiriva-respimat-should-be-used-with-caution-in-patients-with-narrow-angle-glaucoma-prescribers-and-patients-should-be-alert-for-signs-and-symptoms-of-acute-narrow-angle-glaucoma-e-g-eye-pain-or-discomfort-blurred-vision-visual-halos-or-colored-images-in-association-with-red-eyes-from-conjunctival-congestion-and-corneal-edema-instruct-patients-to-consult-a-physician-immediately-should-any-of-these-signs-or-symptoms-develop-since-dizziness-and-blurred-vision-may-occur-with-the-use-of-spiriva-respimat-caution-patients-about-engaging-in-activities-such-as-driving-a-vehicle-or-operating-appliances-or-machinery-spiriva-respimat-should-be-used-with-caution-in-patients-with-urinary-retention-prescribers-and-patients-should-be-alert-for-signs-and-symptoms-of-urinary-retention-e-g-difficulty-passing-urine-painful-urination-especially-in-patients-with-prostatic-hyperplasia-or-bladder-neck-obstruction-instruct-patients-to-consult-a-physician-immediately-should-any-of-these-signs-or-symptoms-develop-patients-with-moderate-to-severe-renal-impairment-creatinine-clearance-of-60-m-l-min-treated-with-spiriva-respimat-should-be-monitored-closely-for-anticholinergic-side-effects-the-most-common-adverse-reactions-2-incidence-and-higher-than-placebo-with-spiriva-respimat-placebo-in-asthma-trials-in-adults-were-pharyngitis-15-9-12-4-headache-3-8-2-7-bronchitis-3-3-1-4-and-sinusitis-2-7-1-4-the-adverse-reaction-profile-for-adolescent-and-pediatric-patients-was-comparable-to-that-observed-in-adult-patients-with-asthma-spiriva-respimat-may-interact-additively-with-concomitantly-used-anticholinergic-medications-avoid-administration-of-spiriva-respimat-with-other-anticholinergic-containing-drugs-inform-patients-not-to-spray-spiriva-respimat-into-the-eyes-as-this-may-cause-blurring-of-vision-and-pupil-dilation-please-see-full-prescribing-information-including-instructions-for-use-for-spiriva-respimat-cl-svr-0044-2-15-2017-span9 {
    color: #191919;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 1rem;
    line-height: 1.5rem;
    font-weight: 400;
}

.frame-956 {
    display: flex;
    flex-direction: row;
    gap: 2rem;
    align-items: center;
    justify-content: flex-start;
    position: absolute;
    left: 42.6875rem;
    top: 68.5rem;
}

.line-26 {
    margin-top: -0.0625rem;
    border-style: solid;
    border-color: #b6cdbf;
    border-width: 0.0625rem 0 0 0;
    align-self: stretch;
    flex-shrink: 0;
    width: 7.25rem;
    position: relative;
    transform-origin: 0 0;
    transform: rotate(90deg) scale(1, 1);
}

.frame-955 {
    display: flex;
    flex-direction: column;
    gap: 0.5rem;
    align-items: flex-start;
    justify-content: flex-start;
    align-self: stretch;
    flex-shrink: 0;
    width: 36rem;
    position: relative;
}

.frame-953 {
    display: flex;
    flex-direction: column;
    gap: 1rem;
    align-items: flex-start;
    justify-content: flex-start;
    align-self: stretch;
    flex-shrink: 0;
    position: relative;
}

.indication {
    color: #191919;
    text-align: left;
    font-family: "BoehringerForwardText-Md", sans-serif;
    font-size: 1.1875rem;
    line-height: 1.75rem;
    font-weight: 400;
    position: relative;
    align-self: stretch;
}

.spiriva-respimat-1-25-mcg-is-a-bronchodilator-indicated-for-the-long-term-once-daily-maintenance-treatment-of-asthma-in-patients-6-years-of-age-and-older-spiriva-respimat-is-not-indicated-for-relief-of-acute-bronchospasm {
    color: #191919;
    text-align: left;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 1rem;
    line-height: 1.5rem;
    font-weight: 400;
    position: relative;
    align-self: stretch;
}

.group-865 {
    width: 78rem;
    height: 23.75rem;
    position: static;
}

.rectangle-37 {
    background: #ffffff;
    width: 78rem;
    height: 23.75rem;
    position: absolute;
    left: 0rem;
    top: 125.75rem;
}

.group-864 {
    width: 76rem;
    height: 15.75rem;
    position: static;
}

.line-27 {
    margin-top: -0.0625rem;
    border-style: solid;
    border-color: #e5e3de;
    border-width: 0.0625rem 0 0 0;
    width: 76rem;
    height: 0rem;
    position: absolute;
    left: 4.6875rem;
    top: 127.75rem;
}

.references {
    color: #191919;
    text-align: left;
    font-family: "BoehringerForwardText-Md", sans-serif;
    font-size: 1rem;
    line-height: 1.5rem;
    font-weight: 400;
    text-transform: uppercase;
    position: absolute;
    left: 4.6875rem;
    top: 128.5rem;
    width: 76rem;
}

.global-initiative-for-asthma-gina-global-strategy-for-asthma-management-and-prevention-accessed-november-16-2023-https-ginasthma-org-wp-content-uploads-2023-07-gina-2023-full-report-23-07-06-wms-pdf-chen-w-tran-tn-sadatsafavi-m-et-al-impact-of-initiating-biologics-in-patients-with-severe-asthma-on-long-term-oral-corticosteroids-or-frequent-rescue-steroids-glitter-data-from-the-international-severe-asthma-registry-j-allergy-clin-immunol-pract-2023-11-9-2732-2747-spiriva-respimat-prescribing-information-ridgefield-ct-boehringer-ingelheim-pharmaceuticals-inc-november-2021-kerstjens-ham-casale-tb-bleecker-er-et-al-tiotropium-or-salmeterol-as-add-on-therapy-to-inhaled-corticosteroids-for-patients-with-moderate-symptomatic-asthma-two-replicate-double-blind-placebo-controlled-parallel-group-active-comparator-randomised-trials-lancet-respir-med-2015-3-5-367-376-hanada-s-wada-s-ohno-t-sawaguchi-h-muraki-m-tohda-y-questionnaire-on-switching-from-the-tiotropium-handi-haler-to-the-respimat-inhaler-in-patients-with-chronic-obstructive-pulmonary-disease-changes-in-handling-and-preferences-immediately-and-several-years-after-the-switch-int-j-chron-obstruct-pulmon-dis-2015-10-69-77-data-on-file-boehringer-ingelheim-pharmaceuticals-inc {
    color: #2e2d2c;
    text-align: left;
    font-family: "-", sans-serif;
    font-size: 0.75rem;
    font-weight: 400;
    position: absolute;
    left: 4.6875rem;
    top: 131rem;
    width: 76rem;
}

.global-initiative-for-asthma-gina-global-strategy-for-asthma-management-and-prevention-accessed-november-16-2023-https-ginasthma-org-wp-content-uploads-2023-07-gina-2023-full-report-23-07-06-wms-pdf-chen-w-tran-tn-sadatsafavi-m-et-al-impact-of-initiating-biologics-in-patients-with-severe-asthma-on-long-term-oral-corticosteroids-or-frequent-rescue-steroids-glitter-data-from-the-international-severe-asthma-registry-j-allergy-clin-immunol-pract-2023-11-9-2732-2747-spiriva-respimat-prescribing-information-ridgefield-ct-boehringer-ingelheim-pharmaceuticals-inc-november-2021-kerstjens-ham-casale-tb-bleecker-er-et-al-tiotropium-or-salmeterol-as-add-on-therapy-to-inhaled-corticosteroids-for-patients-with-moderate-symptomatic-asthma-two-replicate-double-blind-placebo-controlled-parallel-group-active-comparator-randomised-trials-lancet-respir-med-2015-3-5-367-376-hanada-s-wada-s-ohno-t-sawaguchi-h-muraki-m-tohda-y-questionnaire-on-switching-from-the-tiotropium-handi-haler-to-the-respimat-inhaler-in-patients-with-chronic-obstructive-pulmonary-disease-changes-in-handling-and-preferences-immediately-and-several-years-after-the-switch-int-j-chron-obstruct-pulmon-dis-2015-10-69-77-data-on-file-boehringer-ingelheim-pharmaceuticals-inc-span {
    color: #2e2d2c;
    list-style-type: decimal;
    padding-left: 1em;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 0.75rem;
    font-weight: 400;
}

.global-initiative-for-asthma-gina-global-strategy-for-asthma-management-and-prevention-accessed-november-16-2023-https-ginasthma-org-wp-content-uploads-2023-07-gina-2023-full-report-23-07-06-wms-pdf-chen-w-tran-tn-sadatsafavi-m-et-al-impact-of-initiating-biologics-in-patients-with-severe-asthma-on-long-term-oral-corticosteroids-or-frequent-rescue-steroids-glitter-data-from-the-international-severe-asthma-registry-j-allergy-clin-immunol-pract-2023-11-9-2732-2747-spiriva-respimat-prescribing-information-ridgefield-ct-boehringer-ingelheim-pharmaceuticals-inc-november-2021-kerstjens-ham-casale-tb-bleecker-er-et-al-tiotropium-or-salmeterol-as-add-on-therapy-to-inhaled-corticosteroids-for-patients-with-moderate-symptomatic-asthma-two-replicate-double-blind-placebo-controlled-parallel-group-active-comparator-randomised-trials-lancet-respir-med-2015-3-5-367-376-hanada-s-wada-s-ohno-t-sawaguchi-h-muraki-m-tohda-y-questionnaire-on-switching-from-the-tiotropium-handi-haler-to-the-respimat-inhaler-in-patients-with-chronic-obstructive-pulmonary-disease-changes-in-handling-and-preferences-immediately-and-several-years-after-the-switch-int-j-chron-obstruct-pulmon-dis-2015-10-69-77-data-on-file-boehringer-ingelheim-pharmaceuticals-inc-span2 {
    color: #2e2d2c;
    list-style-type: decimal;
    padding-left: 1em;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 0.75rem;
    font-weight: 400;
    text-decoration: underline;
}

.global-initiative-for-asthma-gina-global-strategy-for-asthma-management-and-prevention-accessed-november-16-2023-https-ginasthma-org-wp-content-uploads-2023-07-gina-2023-full-report-23-07-06-wms-pdf-chen-w-tran-tn-sadatsafavi-m-et-al-impact-of-initiating-biologics-in-patients-with-severe-asthma-on-long-term-oral-corticosteroids-or-frequent-rescue-steroids-glitter-data-from-the-international-severe-asthma-registry-j-allergy-clin-immunol-pract-2023-11-9-2732-2747-spiriva-respimat-prescribing-information-ridgefield-ct-boehringer-ingelheim-pharmaceuticals-inc-november-2021-kerstjens-ham-casale-tb-bleecker-er-et-al-tiotropium-or-salmeterol-as-add-on-therapy-to-inhaled-corticosteroids-for-patients-with-moderate-symptomatic-asthma-two-replicate-double-blind-placebo-controlled-parallel-group-active-comparator-randomised-trials-lancet-respir-med-2015-3-5-367-376-hanada-s-wada-s-ohno-t-sawaguchi-h-muraki-m-tohda-y-questionnaire-on-switching-from-the-tiotropium-handi-haler-to-the-respimat-inhaler-in-patients-with-chronic-obstructive-pulmonary-disease-changes-in-handling-and-preferences-immediately-and-several-years-after-the-switch-int-j-chron-obstruct-pulmon-dis-2015-10-69-77-data-on-file-boehringer-ingelheim-pharmaceuticals-inc-span3 {
    color: #2e2d2c;
    list-style-type: decimal;
    padding-left: 1em;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 0.75rem;
    font-weight: 400;
}

.global-initiative-for-asthma-gina-global-strategy-for-asthma-management-and-prevention-accessed-november-16-2023-https-ginasthma-org-wp-content-uploads-2023-07-gina-2023-full-report-23-07-06-wms-pdf-chen-w-tran-tn-sadatsafavi-m-et-al-impact-of-initiating-biologics-in-patients-with-severe-asthma-on-long-term-oral-corticosteroids-or-frequent-rescue-steroids-glitter-data-from-the-international-severe-asthma-registry-j-allergy-clin-immunol-pract-2023-11-9-2732-2747-spiriva-respimat-prescribing-information-ridgefield-ct-boehringer-ingelheim-pharmaceuticals-inc-november-2021-kerstjens-ham-casale-tb-bleecker-er-et-al-tiotropium-or-salmeterol-as-add-on-therapy-to-inhaled-corticosteroids-for-patients-with-moderate-symptomatic-asthma-two-replicate-double-blind-placebo-controlled-parallel-group-active-comparator-randomised-trials-lancet-respir-med-2015-3-5-367-376-hanada-s-wada-s-ohno-t-sawaguchi-h-muraki-m-tohda-y-questionnaire-on-switching-from-the-tiotropium-handi-haler-to-the-respimat-inhaler-in-patients-with-chronic-obstructive-pulmonary-disease-changes-in-handling-and-preferences-immediately-and-several-years-after-the-switch-int-j-chron-obstruct-pulmon-dis-2015-10-69-77-data-on-file-boehringer-ingelheim-pharmaceuticals-inc-span4 {
    color: #2e2d2c;
    list-style-type: decimal;
    padding-left: 1em;
    font-family: "BoehringerForwardText-Italic", sans-serif;
    font-size: 0.75rem;
    font-weight: 400;
    font-style: italic;
}

.global-initiative-for-asthma-gina-global-strategy-for-asthma-management-and-prevention-accessed-november-16-2023-https-ginasthma-org-wp-content-uploads-2023-07-gina-2023-full-report-23-07-06-wms-pdf-chen-w-tran-tn-sadatsafavi-m-et-al-impact-of-initiating-biologics-in-patients-with-severe-asthma-on-long-term-oral-corticosteroids-or-frequent-rescue-steroids-glitter-data-from-the-international-severe-asthma-registry-j-allergy-clin-immunol-pract-2023-11-9-2732-2747-spiriva-respimat-prescribing-information-ridgefield-ct-boehringer-ingelheim-pharmaceuticals-inc-november-2021-kerstjens-ham-casale-tb-bleecker-er-et-al-tiotropium-or-salmeterol-as-add-on-therapy-to-inhaled-corticosteroids-for-patients-with-moderate-symptomatic-asthma-two-replicate-double-blind-placebo-controlled-parallel-group-active-comparator-randomised-trials-lancet-respir-med-2015-3-5-367-376-hanada-s-wada-s-ohno-t-sawaguchi-h-muraki-m-tohda-y-questionnaire-on-switching-from-the-tiotropium-handi-haler-to-the-respimat-inhaler-in-patients-with-chronic-obstructive-pulmonary-disease-changes-in-handling-and-preferences-immediately-and-several-years-after-the-switch-int-j-chron-obstruct-pulmon-dis-2015-10-69-77-data-on-file-boehringer-ingelheim-pharmaceuticals-inc-span5 {
    color: #2e2d2c;
    list-style-type: decimal;
    padding-left: 1em;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 0.75rem;
    font-weight: 400;
}

.global-initiative-for-asthma-gina-global-strategy-for-asthma-management-and-prevention-accessed-november-16-2023-https-ginasthma-org-wp-content-uploads-2023-07-gina-2023-full-report-23-07-06-wms-pdf-chen-w-tran-tn-sadatsafavi-m-et-al-impact-of-initiating-biologics-in-patients-with-severe-asthma-on-long-term-oral-corticosteroids-or-frequent-rescue-steroids-glitter-data-from-the-international-severe-asthma-registry-j-allergy-clin-immunol-pract-2023-11-9-2732-2747-spiriva-respimat-prescribing-information-ridgefield-ct-boehringer-ingelheim-pharmaceuticals-inc-november-2021-kerstjens-ham-casale-tb-bleecker-er-et-al-tiotropium-or-salmeterol-as-add-on-therapy-to-inhaled-corticosteroids-for-patients-with-moderate-symptomatic-asthma-two-replicate-double-blind-placebo-controlled-parallel-group-active-comparator-randomised-trials-lancet-respir-med-2015-3-5-367-376-hanada-s-wada-s-ohno-t-sawaguchi-h-muraki-m-tohda-y-questionnaire-on-switching-from-the-tiotropium-handi-haler-to-the-respimat-inhaler-in-patients-with-chronic-obstructive-pulmonary-disease-changes-in-handling-and-preferences-immediately-and-several-years-after-the-switch-int-j-chron-obstruct-pulmon-dis-2015-10-69-77-data-on-file-boehringer-ingelheim-pharmaceuticals-inc-span6 {
    color: #2e2d2c;
    list-style-type: decimal;
    padding-left: 1em;
    font-family: "BoehringerForwardText-Italic", sans-serif;
    font-size: 0.75rem;
    font-weight: 400;
    font-style: italic;
}

.global-initiative-for-asthma-gina-global-strategy-for-asthma-management-and-prevention-accessed-november-16-2023-https-ginasthma-org-wp-content-uploads-2023-07-gina-2023-full-report-23-07-06-wms-pdf-chen-w-tran-tn-sadatsafavi-m-et-al-impact-of-initiating-biologics-in-patients-with-severe-asthma-on-long-term-oral-corticosteroids-or-frequent-rescue-steroids-glitter-data-from-the-international-severe-asthma-registry-j-allergy-clin-immunol-pract-2023-11-9-2732-2747-spiriva-respimat-prescribing-information-ridgefield-ct-boehringer-ingelheim-pharmaceuticals-inc-november-2021-kerstjens-ham-casale-tb-bleecker-er-et-al-tiotropium-or-salmeterol-as-add-on-therapy-to-inhaled-corticosteroids-for-patients-with-moderate-symptomatic-asthma-two-replicate-double-blind-placebo-controlled-parallel-group-active-comparator-randomised-trials-lancet-respir-med-2015-3-5-367-376-hanada-s-wada-s-ohno-t-sawaguchi-h-muraki-m-tohda-y-questionnaire-on-switching-from-the-tiotropium-handi-haler-to-the-respimat-inhaler-in-patients-with-chronic-obstructive-pulmonary-disease-changes-in-handling-and-preferences-immediately-and-several-years-after-the-switch-int-j-chron-obstruct-pulmon-dis-2015-10-69-77-data-on-file-boehringer-ingelheim-pharmaceuticals-inc-span7 {
    color: #2e2d2c;
    list-style-type: decimal;
    padding-left: 1em;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 0.75rem;
    font-weight: 400;
}

.global-initiative-for-asthma-gina-global-strategy-for-asthma-management-and-prevention-accessed-november-16-2023-https-ginasthma-org-wp-content-uploads-2023-07-gina-2023-full-report-23-07-06-wms-pdf-chen-w-tran-tn-sadatsafavi-m-et-al-impact-of-initiating-biologics-in-patients-with-severe-asthma-on-long-term-oral-corticosteroids-or-frequent-rescue-steroids-glitter-data-from-the-international-severe-asthma-registry-j-allergy-clin-immunol-pract-2023-11-9-2732-2747-spiriva-respimat-prescribing-information-ridgefield-ct-boehringer-ingelheim-pharmaceuticals-inc-november-2021-kerstjens-ham-casale-tb-bleecker-er-et-al-tiotropium-or-salmeterol-as-add-on-therapy-to-inhaled-corticosteroids-for-patients-with-moderate-symptomatic-asthma-two-replicate-double-blind-placebo-controlled-parallel-group-active-comparator-randomised-trials-lancet-respir-med-2015-3-5-367-376-hanada-s-wada-s-ohno-t-sawaguchi-h-muraki-m-tohda-y-questionnaire-on-switching-from-the-tiotropium-handi-haler-to-the-respimat-inhaler-in-patients-with-chronic-obstructive-pulmonary-disease-changes-in-handling-and-preferences-immediately-and-several-years-after-the-switch-int-j-chron-obstruct-pulmon-dis-2015-10-69-77-data-on-file-boehringer-ingelheim-pharmaceuticals-inc-span8 {
    color: #2e2d2c;
    list-style-type: decimal;
    padding-left: 1em;
    font-family: "BoehringerForwardText-Italic", sans-serif;
    font-size: 0.75rem;
    font-weight: 400;
    font-style: italic;
}

.global-initiative-for-asthma-gina-global-strategy-for-asthma-management-and-prevention-accessed-november-16-2023-https-ginasthma-org-wp-content-uploads-2023-07-gina-2023-full-report-23-07-06-wms-pdf-chen-w-tran-tn-sadatsafavi-m-et-al-impact-of-initiating-biologics-in-patients-with-severe-asthma-on-long-term-oral-corticosteroids-or-frequent-rescue-steroids-glitter-data-from-the-international-severe-asthma-registry-j-allergy-clin-immunol-pract-2023-11-9-2732-2747-spiriva-respimat-prescribing-information-ridgefield-ct-boehringer-ingelheim-pharmaceuticals-inc-november-2021-kerstjens-ham-casale-tb-bleecker-er-et-al-tiotropium-or-salmeterol-as-add-on-therapy-to-inhaled-corticosteroids-for-patients-with-moderate-symptomatic-asthma-two-replicate-double-blind-placebo-controlled-parallel-group-active-comparator-randomised-trials-lancet-respir-med-2015-3-5-367-376-hanada-s-wada-s-ohno-t-sawaguchi-h-muraki-m-tohda-y-questionnaire-on-switching-from-the-tiotropium-handi-haler-to-the-respimat-inhaler-in-patients-with-chronic-obstructive-pulmonary-disease-changes-in-handling-and-preferences-immediately-and-several-years-after-the-switch-int-j-chron-obstruct-pulmon-dis-2015-10-69-77-data-on-file-boehringer-ingelheim-pharmaceuticals-inc-span9 {
    color: #2e2d2c;
    list-style-type: decimal;
    padding-left: 1em;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 0.75rem;
    font-weight: 400;
}

.group-1141 {
    width: 5rem;
    height: 5rem;
    position: static;
}

.group-1119 {
    width: 3rem;
    height: 3rem;
    position: static;
}

.ellipse-5 {
    background: #ffffff;
    border-radius: 50%;
    width: 3rem;
    height: 3rem;
    position: absolute;
    left: 80.375rem;
    top: 160.6875rem;
}

.image-21 {
    width: 1.5rem;
    height: 1.5rem;
    position: absolute;
    left: 81.125rem;
    top: 161.4375rem;
    object-fit: cover;
}

.rectangle-73 {
    width: 5rem;
    height: 5rem;
    position: absolute;
    left: 80.375rem;
    top: 160.6875rem;
}

.frame-964 {
    background: #00e47c;
    border-radius: 0.9375rem 0.9375rem 0rem 0rem;
    padding: 0.875rem 1.5rem 0.875rem 1.5rem;
    display: flex;
    flex-direction: row;
    gap: 0.75rem;
    align-items: center;
    justify-content: flex-start;
    height: 3rem;
    position: absolute;
    right: -7rem;
    top: 59.8125rem;
    transform-origin: 0 0;
    transform: rotate(-90deg) scale(1, 1);
}

.order-samples {
    color: #08312a;
    text-align: left;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 1rem;
    font-weight: 400;
    position: relative;
}

.group-1161 {
    position: absolute;
    inset: 0;
}

.group-1117 {
    width: 78rem;
    height: 19.3125rem;
    position: static;
}

.rectangle-67 {
    background: #08312a;
    width: 78rem;
    height: 17.5rem;
    position: absolute;
    left: 0rem;
    top: 19.875rem;
}

.when-your-patients-with-asthma-remain-symptomatic-on-ics-laba-add-spiriva-respimat-1-25-mcg {
    color: var(--grey-and-white-white, #ffffff);
    text-align: left;
    font-family: "BoehringerForwardHead-Md", sans-serif;
    font-size: 2.0625rem;
    line-height: 2.75rem;
    font-weight: 400;
    position: absolute;
    left: 44.6875rem;
    top: 24.5rem;
    width: 38.6875rem;
}

.group-1114 {
    width: 10.76625rem;
    height: 3.625rem;
    position: static;
}

.group-1027 {
    width: 10.76625rem;
    height: 3.625rem;
    position: static;
}

.rectangle-32 {
    background: #ffffff;
    border-style: solid;
    border-color: #08312a;
    border-width: 0.0625rem;
    width: 3.625rem;
    height: 3.625rem;
    position: absolute;
    left: 73.10875rem;
    top: 35.5625rem;
}

.chevron-left {
    width: 2rem;
    height: 2rem;
    position: absolute;
    left: 73.92125rem;
    top: 36.375rem;
    overflow: visible;
}

.rectangle-322 {
    background: #ffffff;
    border-style: solid;
    border-color: #08312a;
    border-width: 0.0625rem;
    width: 3.625rem;
    height: 3.625rem;
    position: absolute;
    left: 76.6875rem;
    top: 35.5625rem;
}

.rectangle-323 {
    background: #ffffff;
    border-style: solid;
    border-color: #08312a;
    border-width: 0.0625rem;
    width: 3.625rem;
    height: 3.625rem;
    position: absolute;
    left: 80.25rem;
    top: 35.5625rem;
}

.chevron-right {
    width: 2rem;
    height: 2rem;
    position: absolute;
    left: 81.0625rem;
    top: 36.375rem;
    overflow: visible;
}

.play {
    width: 1.75rem;
    height: 1.75rem;
    position: absolute;
    left: 77.625rem;
    top: 36.5rem;
    overflow: visible;
}

.frame-979 {
    display: flex;
    flex-direction: row;
    gap: 0.5rem;
    align-items: center;
    justify-content: flex-start;
    position: absolute;
    left: 37.9375rem;
    top: 39.0625rem;
}

.rectangle-33 {
    background: #08312a;
    flex-shrink: 0;
    width: 2rem;
    height: 0.125rem;
    position: relative;
}

.rectangle-332 {
    background: #e5e3de;
    flex-shrink: 0;
    width: 2rem;
    height: 0.125rem;
    position: relative;
}

.rectangle-34 {
    background: #e5e3de;
    flex-shrink: 0;
    width: 2rem;
    height: 0.125rem;
    position: relative;
}

.rectangle-352 {
    background: #e5e3de;
    flex-shrink: 0;
    width: 2rem;
    height: 0.125rem;
    position: relative;
}

.mask-group {
    width: 42.6875rem;
    height: 17.5rem;
    position: absolute;
    left: 0rem;
    top: 19.875rem;
    overflow: visible;
}

.group-1230 {
    position: absolute;
    inset: 0;
}

.group-867 {
    width: 100%; /*78rem;*/
    height: 2.5rem;
    position: static;
}

.rectangle-38 {
    background: #ffffff;
    width: 100% ; /*78rem;*/
    height: 2.5rem;
    position: absolute;
    left: 0rem;
    /*top: 149.5rem;*/
}

.group-854 {
    width: 76rem;
    height: 2.5rem;
    position: static;
}

.rectangle-342 {
    width: 72rem;
    height: 2.5rem;
    position: absolute;
    left: 4.6875rem;
    /*top: 149.5rem;*/
}

.frame-939 {
    display: flex;
    flex-direction: row;
    gap: 0.25rem;
    align-items: center;
    justify-content: flex-start;
    position: absolute;
    left: 4.6875rem;
    /*top: 46rem;*/
}

.group-853 {
    flex-shrink: 0;
    width: 2.5rem;
    height: 1rem;
    position: relative;
    overflow: visible;
}

.frame-938 {
    display: flex;
    flex-direction: row;
    gap: 0.5rem;
    align-items: center;
    justify-content: flex-start;
    flex-shrink: 0;
    position: relative;
}

.products2 {
    color: #191919;
    text-align: left;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 0.875rem;
    font-weight: 400;
    position: relative;
}

.group-12 {
    flex-shrink: 0;
    width: 1rem;
    height: 1rem;
    position: relative;
    overflow: visible;
}

.frame-9392 {
    display: flex;
    flex-direction: row;
    gap: 0.5rem;
    align-items: center;
    justify-content: flex-start;
    flex-shrink: 0;
    position: relative;
}

.spiriva-respimat {
    color: #191919;
    text-align: left;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 0.875rem;
    font-weight: 400;
    position: relative;
}

.group-1185 {
    width: 100%; /*78rem;*/
    height: 16.375rem;
    position: static;
}

.group-1143 {
    width: 100%; /*78rem;*/
    height: 16.375rem;
    position: static;
}

.group-8672 {
    width: 100%; /*78rem;*/
    height: 16.375rem;
    position: static;
}

.group-852 {
    width: 100%; /*78rem;*/
    height: 16.375rem;
    position: static;
}

.rectangle-324 {
    background: #08312a;
    width: 100%; /* 78rem;*/
    height: 16.375rem;
    position: absolute;
    left: 0rem;
    /*top: 152rem;*/
}

.group-847 {
    width: 7rem;
    height: 3.5rem;
    position: static;
}

.group-846 {
    width: 7rem;
    height: 3.5rem;
    position: static;
}

.rectangle-333 {
    width: 7rem;
    height: 3.5rem;
    position: absolute;
    left: 4.6875rem;
    /*top: 153.5rem;*/
}

.group-8472 {
    width: 7rem;
    height: 2.12125rem;
    position: static;
}

.group-8462 {
    width: 7rem;
    height: 2.12125rem;
    position: static;
}

.image-5 {
    width: 7rem;
    height: 2.12125rem;
    position: absolute;
    left: 4.6875rem;
    /*top: 154.189375rem;*/
    object-fit: cover;
}

.groupfooterlinks {
    width: 100%; /*47.5625rem;*/
    height: 4.375rem;
    position: static;
}

.groupfooterlinks1 {
    display: flex;
    justify-content: center; /* Horizontal centering */
    align-items: center;
    width: 100%; /*47.5625rem;*/
    height: 6rem;
    position: static;
}

.link1 {
  color: #ffffff !important;
  text-align: right;
  font-family: "BoehringerForwardText-Regular", sans-serif;
  font-size: 0.875rem;
  font-weight: 400;
  position: absolute;
  right: 30rem;
  /*  top: 60rem;*/
  /*width: 40rem;*/
  height: 2.375rem;
  cursor: pointer !important;
  text-decoration: none;
}

  .link1:hover {
    color: #ffffff !important;
    text-align: right;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 0.875rem;
    font-weight: 400;
    position: absolute;
    right: 30rem;
    /*  top: 60rem;*/
    /*width: 40rem;*/
    height: 2.375rem;
    cursor: pointer !important;
    text-decoration: none;
  }

.link2 {
    color: #ffffff !important;
    text-align: right;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 0.875rem;
    font-weight: 400;
    position: absolute;
    right: 25rem;
    /*  top: 60rem;*/
    /*width: 40rem;*/
    height: 2.375rem;
    cursor: pointer !important;
    text-decoration: none;
}

    .link2:hover {
        color: #ffffff !important;
        text-align: right;
        font-family: "BoehringerForwardText-Regular", sans-serif;
        font-size: 0.875rem;
        font-weight: 400;
        position: absolute;
        right: 25rem;
        /*  top: 60rem;*/
        /*width: 40rem;*/
        height: 2.375rem;
        cursor: pointer !important;
        text-decoration: none;
    }


.link3 {
    color: #ffffff !important;
    text-align: right;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 0.875rem;
    font-weight: 400;
    position: absolute;
    right: 15rem;
    /*  top: 60rem;*/
    /*width: 40rem;*/
    height: 2.375rem;
    cursor: pointer !important;
    text-decoration: none;
}

    .link3:hover {
        color: #ffffff !important;
        text-align: right;
        font-family: "BoehringerForwardText-Regular", sans-serif;
        font-size: 0.875rem;
        font-weight: 400;
        position: absolute;
        right: 15rem;
        /*  top: 60rem;*/
        /*width: 40rem;*/
        height: 2.375rem;
        cursor: pointer !important;
        text-decoration: none;
    }


.link4 {
    color: #ffffff !important;
    text-align: right;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 0.875rem;
    font-weight: 400;
    position: absolute;
    right: 10rem;
    /*  top: 60rem;*/
    /*width: 40rem;*/
    height: 2.375rem;
    cursor: pointer !important;
    text-decoration: none;
}

    .link4:hover {
        color: #ffffff !important;
        text-align: right;
        font-family: "BoehringerForwardText-Regular", sans-serif;
        font-size: 0.875rem;
        font-weight: 400;
        position: absolute;
        right: 10rem;
        /*  top: 60rem;*/
        /*width: 40rem;*/
        height: 2.375rem;
        cursor: pointer !important;
        text-decoration: none;
    }


.link5 {
    color: #ffffff !important;
    text-align: right;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 0.875rem;
    font-weight: 400;
    position: absolute;
    right: 5rem;
    /*  top: 60rem;*/
    /*width: 20rem;*/
    height: 2.375rem;
    cursor: pointer !important;
    text-decoration: none;
}

    .link5:hover {
        color: #ffffff !important;
        text-align: right;
        font-family: "BoehringerForwardText-Regular", sans-serif;
        font-size: 0.875rem;
        font-weight: 400;
        position: absolute;
        right: 5rem;
        /*  top: 60rem;*/
        /*width: 20rem;*/
        height: 2.375rem;
        cursor: pointer !important;
        text-decoration: none;
    }



.group-851 {
    width: 100%; /*47.5625rem;*/
    height: 4.375rem;
    position: static;
}

.this-information-is-for-u-s-residents-only-products-discussed-herein-may-have-different-labelling-in-different-countries-use-of-this-site-is-subject-to-the-internet-site-legal-notices-and-disclaimers-and-privacy-notice {
    color: #ffffff;
    text-align: center;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 0.875rem;
    font-weight: 400;
    position: absolute;
    padding-bottom: 5rem;
    /*right: 17rem;*/
    /*  top: 60rem;*/
    width: 47.5625rem;
    height: 2.375rem;
}

.copyright-2024-boehringer-ingelheim-pharmaceuticals-inc-all-rights-reserved-08-24-pc-us-139993 {
    color: #ffffff;
    text-align: center;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 0.75rem;
    font-weight: 400;
    position: absolute;
    /*right: 23rem;*/
    /*top: 165.875rem;*/
    /*bottom: 3rem;*/
    width: 36.75rem;
    height: 1rem;
}

.group-11412 {
    width: 5rem;
    height: 12.21625rem;
    position: static;
}

.ellipse-52 {
    background: #ffffff;
    border-radius: 50%;
    width: 3rem;
    height: 3rem;
    position: absolute;
    left: 80.875rem;
    top: 55.5rem;
}

.image-212 {
    width: 1.5rem;
    height: 1.5rem;
    position: absolute;
    left: 81.625rem;
    top: 56.3rem;
    object-fit: cover;
}

.rectangle-732 {
    width: 5rem;
    height: 5rem;
    position: absolute;
    left: 80.375rem;
    top: 160.71625rem;
}

.group-11442 {
    width: 58.75rem;
    height: 0.9375rem;
    position: static;
}

.frame-937 {
    width: 58.75rem;
    height: 2.625rem;
    position: absolute;
    left: 14.1875rem;
    /*top: 52.3rem;*/
}

.accessibility-statement {
    color: #ffffff;
    text-align: center;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 1rem;
    font-weight: 400;
    position: absolute;
    left: 0rem;
    bottom: 10rem
    /*top: -0.001875rem;*/
}

.terms-of-use {
    color: #ffffff;
    text-align: center;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 1rem;
    font-weight: 400;
    position: absolute;
    left: 7.9375rem;
    /*top: -0.001875rem;*/
}

.imprint {
    color: #ffffff;
    text-align: center;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 1rem;
    font-weight: 400;
    position: absolute;
    left: 15.875rem;
    /*top: -0.001875rem;*/
}

.us-privacy-statement {
    color: #ffffff;
    text-align: center;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 1rem;
    font-weight: 400;
    position: absolute;
    left: 21.25rem;
    /*top: 0rem;*/
}

.consumer-health-data-privacy-statement {
    color: #ffffff;
    text-align: center;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 1rem;
    font-weight: 400;
    position: absolute;
    left: 28.1875rem;
    /*top: 0rem;*/
}

.cookie-statement {
    color: #ffffff;
    text-align: center;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 1rem;
    font-weight: 400;
    position: absolute;
    left: 40.6875rem;
    /*top: 0rem;*/
}

.do-not-sell-or-share-my-personal-data {
    color: #ffffff;
    text-align: center;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 1rem;
    font-weight: 400;
    position: absolute;
    left: 47.625rem;
    /*top: 0rem;*/
}

.frame-9382 {
    width: 22.9375rem;
    height: 1.3125rem;
    position: absolute;
    left: 31.25rem;
    /*top: 57rem;*/
}

.limit-the-use-of-my-sensitive-data {
    color: #ffffff;
    text-align: center;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 1rem;
    font-weight: 400;
    position: absolute;
    left: 0rem;
    /*top: 0rem;*/
}

.contact-us {
    color: #ffffff;
    text-align: center;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 1rem;
    font-weight: 400;
    position: absolute;
    left: 17.75rem;
    /*top: 0rem;*/
}

.frame-942 {
    display: flex;
    flex-direction: row;
    gap: 1.5rem;
    align-items: center;
    justify-content: flex-start;
    height: 1.1875rem;
    position: absolute;
    right: 4.6875rem;
    /*top: 0.8125rem;*/
}

.other-tiotropium-products {
    color: #191919;
    text-align: right;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 0.875rem;
    font-weight: 400;
    position: relative;
}

.prescribing-information {
    color: #191919;
    text-align: right;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 0.875rem;
    font-weight: 400;
    position: relative;
}

.instructions-for-use {
    color: #191919;
    text-align: right;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 0.875rem;
    font-weight: 400;
    position: relative;
}

.group-1198 {
    flex-shrink: 0;
    width: 8.375rem;
    height: 1.6875rem;
    position: static;
}

.frame-1197 {
    border-radius: 0.125rem;
    border-style: solid;
    border-color: #000000;
    border-width: 0.0625rem;
    padding: 0.25rem 0.75rem 0.25rem 0.75rem;
    display: flex;
    flex-direction: row;
    gap: 0.625rem;
    align-items: center;
    justify-content: center;
    width: 8.375rem;
    height: 1.6875rem;
    position: absolute;
    left: 33rem;
    top: -0.25rem;
}

.patient-website {
    color: #191919;
    text-align: left;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 0.875rem;
    font-weight: 400;
    position: relative;
}

.frame-941 {
    border-style: solid;
    border-color: #e5e3de;
    border-width: 0.0625rem;
    padding: 0.25rem 0.75rem 0.25rem 0.75rem;
    display: flex;
    flex-direction: column;
    gap: 0.625rem;
    align-items: flex-start;
    justify-content: flex-start;
    height: 1.6875rem;
    position: absolute;
    left: 27.4375rem;
    top: 0.5625rem;
}

.frame-940 {
    display: flex;
    flex-direction: row;
    gap: 0.5rem;
    align-items: center;
    justify-content: flex-start;
    flex-shrink: 0;
    position: relative;
}

.select-indication {
    color: #191919;
    text-align: left;
    font-family: "BoehringerForwardText-Regular", sans-serif;
    font-size: 0.875rem;
    font-weight: 400;
    position: relative;
}

.group-34 {
    flex-shrink: 0;
    width: 1rem;
    height: 1rem;
    position: relative;
    overflow: visible;
}